HRP20201118T1 - Izolacija i pročišćavanje prot-il-13 protutijela uporabom protein a afinitetne kromatografije - Google Patents
Izolacija i pročišćavanje prot-il-13 protutijela uporabom protein a afinitetne kromatografije Download PDFInfo
- Publication number
- HRP20201118T1 HRP20201118T1 HRP20201118TT HRP20201118T HRP20201118T1 HR P20201118 T1 HRP20201118 T1 HR P20201118T1 HR P20201118T T HRP20201118T T HR P20201118TT HR P20201118 T HRP20201118 T HR P20201118T HR P20201118 T1 HRP20201118 T1 HR P20201118T1
- Authority
- HR
- Croatia
- Prior art keywords
- sample
- hic
- reduced
- mixture
- antibody
- Prior art date
Links
- 238000001042 affinity chromatography Methods 0.000 title claims 3
- 102000004169 proteins and genes Human genes 0.000 title claims 3
- 108090000623 proteins and genes Proteins 0.000 title claims 3
- 238000002955 isolation Methods 0.000 title 1
- 238000000746 purification Methods 0.000 title 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000000872 buffer Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 230000005526 G1 to G0 transition Effects 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000012539 chromatography resin Substances 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 125000001165 hydrophobic group Chemical group 0.000 claims 2
- 238000005342 ion exchange Methods 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- 230000020477 pH reduction Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 229920000936 Agarose Polymers 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003957 anion exchange resin Substances 0.000 claims 1
- 150000001450 anions Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 238000011118 depth filtration Methods 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (5)
1. Postupak proizvodnje preparata protu-IL-13 protutijela s reduciranim proteinom stanice domaćina (reduciran HCP) iz mješavine uzorka koji sadrži protu-IL-13 protutijelo i najmanje jedan HCP, pri čemu navedeni postupak sadrži:
(a) filtriranje navedene mješavine uzorka s filtrom za dubinsku filtraciju i sakupljanje dubinski filtrirane mješavine uzorka;
(b) dodirivanje dubinski filtrirane mješavine uzorka s Protein A afinitetnom kromatografskom smolom, ispiranje navedene afinitetne kromatografske smole puferom koji sadrži 25 mM Tris, 100 mM NaCl, pH 7.2, zatim ispiranje puferom koji sadrži 20 mM natrij citrat/limunsku kiselinu, 0.5 M NaCl, pH 6, i zatim puferom koji sadrži 25 mM Tris, 100 mM NaCl, pH 7.2 i sakupljanje afinitetnog kromatografskog uzorka;
(c) podvrgavanje navedenog afinitetnog kromatografskog uzorka redukciji u pH na taj način formirajući uzorak s reduciranim pH, pri čemu navedeni uzorak s reduciranim pH ima pH od oko 3 do oko 4;
(d) podešavanje pH navedenog uzorka s reduciranim pH do pH od oko 4.5 do oko 8.5 i dodirivanje navedenog uzorka s podešenim pH s anionskom izmjenjivačkom smolom koja sadrži kvaternarni aminoetil (QAE) anionski supstituent i sakupljanje ionskog izmjenjivačkog uzorka; i
(e) dodirivanje navedenog ionskog izmjenjivačkog uzorka s materijalom za kromatografiju s hidrofobnom interakcijom (HIC) i sakupljanje HIC uzorka, pri čemu navedeni HIC uzorak sadrži navedeni preparat protutijela s reduciranim HCP, pri čemu „oko“ označava do 20% veće od ili manje od referentne vrijednosti, i pri čemu navedeno protu-IL-13 protutijelo je humanizirano IgA1, IgA2, IgG1, IgG2, IgG4, ili IgM protutijelo koje sadrži varijabilnu regiju teškog lanca od
EVTLRESGPGLVKPTQTLTLTCTLYGFSLSTSDMGVDWIRQPPGKGLEWLAHIWWDDVKRYNPALKSRLTISKDTSKNQVVLKLTSVDPVDTATYYCARTVSSGYIYYAMDYWGQGTLVTVSS i varijabilnu regiju lakog lanca od
[image]
2. Postupak sukladno patentnom zahtjevu 1, naznačen time što navedena redukcija u pH u koraku (c) je postignuta miješanjem odgovarajuće kiseline s navedenom mješavinom uzorka, izborno pri čemu navedena odgovarajuća kiselina je odabrana iz skupine sastavljene od limunske kiseline, octene kiseline i kaprilne kiseline.
3. Postupak sukladno patentnom zahtjevu 1, naznačen time što navedeni HIC materijal je:
(i) HIC kolona čija stacionarna faza sadrži hidrofobne skupine, ili
(ii) HIC kolona čija stacionarna faza sadrži hidrofobne skupine odabrane iz skupine sastavljene od alkil-skupine, aril-skupine i njihove kombinacije; ili
(iii) agarozna smola supstituirana s fenil skupinom.
4. Postupak sukladno patentnom zahtjevu 1 koji dodatno sadrži korak filtriranja, pri čemu navedeni uzorak HIC je podvrgnut filtriranju da bi se uklonile virusne čestice i da bi se olakšala razmjena pufera.
5. Postupak sukladno patentnom zahtjevu 1 ili 2, naznačen time što navedeni uzorak s reduciranim pH u koraku (c) ima pH od oko 3.5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25341109P | 2009-10-20 | 2009-10-20 | |
| EP15189425.0A EP3037104B1 (en) | 2009-10-20 | 2010-10-20 | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201118T1 true HRP20201118T1 (hr) | 2020-10-30 |
Family
ID=43900936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201118TT HRP20201118T1 (hr) | 2009-10-20 | 2020-07-15 | Izolacija i pročišćavanje prot-il-13 protutijela uporabom protein a afinitetne kromatografije |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US8491904B2 (hr) |
| EP (2) | EP2491055A2 (hr) |
| JP (1) | JP5914342B2 (hr) |
| KR (2) | KR101830596B1 (hr) |
| CN (2) | CN102711828B (hr) |
| AU (1) | AU2010310748C1 (hr) |
| BR (1) | BR112012009289B8 (hr) |
| CA (1) | CA2775595A1 (hr) |
| CY (1) | CY1123952T1 (hr) |
| DK (1) | DK3037104T3 (hr) |
| ES (1) | ES2813398T3 (hr) |
| HR (1) | HRP20201118T1 (hr) |
| HU (1) | HUE053489T2 (hr) |
| IL (1) | IL218897A (hr) |
| IN (1) | IN2012DN02778A (hr) |
| LT (1) | LT3037104T (hr) |
| MX (2) | MX2012004711A (hr) |
| NZ (2) | NZ627668A (hr) |
| PL (1) | PL3037104T3 (hr) |
| PT (1) | PT3037104T (hr) |
| RS (1) | RS60577B1 (hr) |
| RU (1) | RU2603055C2 (hr) |
| SG (1) | SG10201406713XA (hr) |
| SI (1) | SI3037104T1 (hr) |
| SM (1) | SMT202000470T1 (hr) |
| TW (1) | TWI515202B (hr) |
| WO (1) | WO2011050071A2 (hr) |
| ZA (1) | ZA201202720B (hr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009068649A2 (en) * | 2007-11-30 | 2009-06-04 | Glaxo Group Limited | Antigen-binding constructs |
| RU2551237C2 (ru) | 2008-10-20 | 2015-05-20 | Эббви Инк | Инактивация вируса при очистке антител |
| RU2520838C2 (ru) * | 2008-10-20 | 2014-06-27 | Эббви Инк | Выделение и очистка антител с использованием аффинной хроматографии на основе белка а |
| RS60577B1 (sr) | 2009-10-20 | 2020-08-31 | Abbvie Inc | Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije |
| KR101627597B1 (ko) | 2010-07-30 | 2016-06-08 | 이엠디 밀리포어 코포레이션 | 부직포 층 |
| TWI700093B (zh) | 2011-03-16 | 2020-08-01 | 法商賽諾菲公司 | 雙重ｖ區類抗體蛋白質之用途 |
| US20150038362A1 (en) * | 2012-02-27 | 2015-02-05 | Biogen Idec Ma Inc. | High-Throughput Method For Sialic Acid Quantitation |
| JP6592426B2 (ja) | 2013-03-15 | 2019-10-16 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製 |
| AU2014265624B2 (en) * | 2013-05-15 | 2019-09-12 | Medimmune Limited | Purification of recombinantly produced polypeptides |
| TWI596107B (zh) | 2013-06-25 | 2017-08-21 | 卡地拉保健有限公司 | 單株抗體之新穎純化方法 |
| SG11201508835YA (en) | 2013-07-12 | 2015-11-27 | Merck Patent Gmbh | Removal of fragments from a sample containing a target protein using activated carbon |
| EP4331605A3 (en) * | 2013-09-13 | 2024-05-22 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
| JP6546178B2 (ja) | 2013-09-13 | 2019-07-17 | ジェネンテック， インコーポレイテッド | 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法 |
| JPWO2015041218A1 (ja) * | 2013-09-17 | 2017-03-02 | 株式会社カネカ | 新規抗体精製方法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎＭｅｔｈｏｄａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎｍｅｔｈｏｄｕｓｉｎｇＣａｔｉｏｎＥｘｃｈａｎｇｅｒａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ） |
| CN105017418B (zh) * | 2014-03-27 | 2021-02-23 | 上海药明康德新药开发有限公司 | 单克隆抗体纯化工艺方法 |
| FR3025515B1 (fr) * | 2014-09-05 | 2016-09-09 | Lab Francais Du Fractionnement | Procede de purification d'un anticorps monoclonal |
| AR102198A1 (es) | 2014-10-09 | 2017-02-08 | Regeneron Pharma | Proceso para reducir partículas subvisibles en una formulación farmacéutica |
| SG11201703399QA (en) | 2014-12-08 | 2017-05-30 | Emd Millipore Corp | Mixed bed ion exchange adsorber |
| ES2995985T3 (en) | 2015-08-13 | 2025-02-11 | Amgen Inc | Charged depth filtration of antigen-binding proteins |
| HK1259368A1 (zh) * | 2015-08-20 | 2019-11-29 | F. Hoffmann-La Roche Ag | Fkpa的纯化及其用於生产重组多肽的用途 |
| CN114617962A (zh) | 2016-04-27 | 2022-06-14 | 艾伯维公司 | 使用抗-il-13抗体治疗il-13活性在其中有害的疾病的方法 |
| IL309453A (en) | 2016-08-16 | 2024-02-01 | Regeneron Pharma | A method for quantifying individual antibodies from a mixture |
| IL289895B (en) | 2016-10-25 | 2022-09-01 | Regeneron Pharma | Methods and systems for analysis of chromatography data |
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018140887A1 (en) * | 2017-01-30 | 2018-08-02 | Regeneron Pharmaceuticals, Inc. | Method for reducing bioburden in chromatography |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| TWI679209B (zh) * | 2017-04-14 | 2019-12-11 | 南韓商Ｃｊ醫藥健康股份有限公司 | 使用陽離子交換層析法純化同功抗體之方法 |
| JP7097433B2 (ja) * | 2017-08-17 | 2022-07-07 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法 |
| CA3073935A1 (en) | 2017-09-19 | 2019-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of reducing particle formation and compositions formed thereby |
| TW202448568A (zh) | 2018-07-02 | 2024-12-16 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| SG11202100653YA (en) * | 2018-07-25 | 2021-02-25 | Daiichi Sankyo Co Ltd | Effective method for manufacturing antibody-drug conjugate |
| US12358999B2 (en) | 2018-07-27 | 2025-07-15 | Daiichi Sankyo Company, Limited | Protein recognizing drug moiety of antibody-drug conjugate |
| CN110818789B (zh) * | 2018-08-07 | 2023-02-28 | 三生国健药业（上海）股份有限公司 | 一种高纯度食蟹猴白细胞介素17a的纯化方法 |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| TWI871300B (zh) * | 2019-01-28 | 2025-02-01 | 美商安進公司 | 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程 |
| AR119097A1 (es) * | 2019-06-05 | 2021-11-24 | Seattle Genetics Inc | Métodos de purificación de anticuerpos enmascarados |
| US20220259261A1 (en) * | 2019-08-01 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Method for viral inactivation |
| TW202128745A (zh) | 2019-12-06 | 2021-08-01 | 美商再生元醫藥公司 | 抗ｖｅｇｆ蛋白組合物及其製備方法 |
| EP4309722A3 (en) | 2019-12-13 | 2024-08-07 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| MY210396A (en) | 2020-01-17 | 2025-09-18 | Regeneron Pharma | Hydrophobic interaction chromatography for viral clearance |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| CN112326966A (zh) * | 2020-11-02 | 2021-02-05 | 杭州昱鼎生物科技有限公司 | 一种新型冠状病毒抗原的快速检测试剂盒及其制备方法和应用 |
| WO2025029614A1 (en) * | 2023-07-28 | 2025-02-06 | Amgen Inc. | A method for equilibrating a chromatography medium |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE266710C (hr) | ||||
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4534972A (en) | 1983-03-29 | 1985-08-13 | Miles Laboratories, Inc. | Protein compositions substantially free from infectious agents |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE4041205A1 (de) | 1990-12-21 | 1992-06-25 | Schloemann Siemag Ag | Verfahren und anlage zum auswalzen von warmbreitband aus stranggegossenen duennbrammen |
| DK1279731T3 (da) | 1991-03-01 | 2007-09-24 | Dyax Corp | Fremgangsmåde til udvikling af bindende miniproteiner |
| ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5457178A (en) * | 1993-07-07 | 1995-10-10 | Fmc Corporation | Insecticidally effective spider toxin |
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| EP0871436A4 (en) * | 1995-06-30 | 1999-10-20 | Smithkline Beecham Corp | USE OF STAT 6 SH2 DOMAINE-SPECIFIC COMPOUNDS FOR TREATING ALLERGIC REACTIONS |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US6955917B2 (en) * | 1997-06-20 | 2005-10-18 | Bayer Healthcare Llc | Chromatographic method for high yield purification and viral inactivation of antibodies |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| EP1970448A1 (en) | 2001-05-11 | 2008-09-17 | Kirin Pharma Kabushiki Kaisha | Human artificial chromosome containting human antibody lambda light chain and non-human animal containting the human artificial chromosome capable of genetic transmission |
| US7646782B1 (en) | 2001-07-30 | 2010-01-12 | Primrose Donald R | Data link/physical layer packet buffering and flushing |
| CA2499269A1 (en) * | 2002-09-17 | 2004-04-01 | Gtc Biotherapeutics, Inc. | Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds |
| PT1601697E (pt) * | 2003-02-28 | 2007-09-04 | Lonza Biologics Plc | Purificação de anticorpos através de proteína a e cromatografia de troca iónica. |
| GB0304576D0 (en) * | 2003-02-28 | 2003-04-02 | Lonza Biologics Plc | Protein a chromatography |
| EP1678208B1 (en) | 2003-10-27 | 2013-05-15 | Wyeth LLC | Removal of high molecular weight aggregates using hydroxyapatite chromatography |
| DE102004027816A1 (de) * | 2004-06-08 | 2006-01-05 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von Erythropoietin |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| PL1942939T5 (pl) | 2005-09-30 | 2021-10-11 | Medimmune Limited | Kompozycja przeciwciała interleukiny-13 |
| GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
| SG170837A1 (en) * | 2006-04-05 | 2011-05-30 | Abbott Biotech Ltd | Antibody purification |
| BRPI0710820A2 (pt) * | 2006-04-20 | 2011-08-23 | Wyeth Corp | processo para a purificação do vìrus da estomatite vesicular (vsv) do fluido de cultura celular de uma cultura de células de mamìferos infectada com vsv; vsv purificado de acordo com o processo; composição farmacêutica; e composição imunogênica |
| WO2009017491A1 (en) * | 2006-06-14 | 2009-02-05 | Smithkline Beecham Corporation | Methods for purifying antibodies using ceramic hydroxyapatite |
| CN101512008B (zh) * | 2006-09-08 | 2015-04-01 | 艾伯维巴哈马有限公司 | 白介素-13结合蛋白 |
| RU2551237C2 (ru) * | 2008-10-20 | 2015-05-20 | Эббви Инк | Инактивация вируса при очистке антител |
| JP2010209068A (ja) * | 2009-03-11 | 2010-09-24 | Wyeth Llc | 小モジュラー免疫薬タンパク質を精製する方法 |
| RS60577B1 (sr) | 2009-10-20 | 2020-08-31 | Abbvie Inc | Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije |
-
2010
- 2010-10-20 RS RS20200864A patent/RS60577B1/sr unknown
- 2010-10-20 PL PL15189425T patent/PL3037104T3/pl unknown
- 2010-10-20 LT LTEP15189425.0T patent/LT3037104T/lt unknown
- 2010-10-20 AU AU2010310748A patent/AU2010310748C1/en not_active Ceased
- 2010-10-20 NZ NZ627668A patent/NZ627668A/en not_active IP Right Cessation
- 2010-10-20 CA CA2775595A patent/CA2775595A1/en not_active Abandoned
- 2010-10-20 SM SM20200470T patent/SMT202000470T1/it unknown
- 2010-10-20 DK DK15189425.0T patent/DK3037104T3/da active
- 2010-10-20 NZ NZ599100A patent/NZ599100A/en not_active IP Right Cessation
- 2010-10-20 EP EP10777144A patent/EP2491055A2/en not_active Withdrawn
- 2010-10-20 WO PCT/US2010/053388 patent/WO2011050071A2/en not_active Ceased
- 2010-10-20 RU RU2012120751/10A patent/RU2603055C2/ru active
- 2010-10-20 KR KR1020127012851A patent/KR101830596B1/ko active Active
- 2010-10-20 MX MX2012004711A patent/MX2012004711A/es active IP Right Grant
- 2010-10-20 SG SG10201406713XA patent/SG10201406713XA/en unknown
- 2010-10-20 JP JP2012535337A patent/JP5914342B2/ja active Active
- 2010-10-20 KR KR1020177034448A patent/KR20170136649A/ko not_active Ceased
- 2010-10-20 CN CN201080057917.5A patent/CN102711828B/zh active Active
- 2010-10-20 US US12/908,502 patent/US8491904B2/en active Active
- 2010-10-20 SI SI201032028T patent/SI3037104T1/sl unknown
- 2010-10-20 MX MX2014006213A patent/MX341136B/es unknown
- 2010-10-20 EP EP15189425.0A patent/EP3037104B1/en active Active
- 2010-10-20 TW TW099135795A patent/TWI515202B/zh active
- 2010-10-20 BR BR112012009289A patent/BR112012009289B8/pt active IP Right Grant
- 2010-10-20 CN CN201510208066.4A patent/CN104744560A/zh active Pending
- 2010-10-20 ES ES15189425T patent/ES2813398T3/es active Active
- 2010-10-20 PT PT151894250T patent/PT3037104T/pt unknown
- 2010-10-20 HU HUE15189425A patent/HUE053489T2/hu unknown
-
2012
- 2012-03-27 IL IL218897A patent/IL218897A/en active IP Right Grant
- 2012-03-30 IN IN2778DEN2012 patent/IN2012DN02778A/en unknown
- 2012-04-13 ZA ZA2012/02720A patent/ZA201202720B/en unknown
-
2013
- 2013-07-09 US US13/937,946 patent/US9266950B2/en active Active
-
2016
- 2016-01-19 US US15/000,831 patent/US9975948B2/en active Active
-
2018
- 2018-04-06 US US15/947,085 patent/US11390668B2/en active Active
-
2020
- 2020-07-15 HR HRP20201118TT patent/HRP20201118T1/hr unknown
- 2020-08-21 CY CY20201100781T patent/CY1123952T1/el unknown
-
2022
- 2022-05-17 US US17/745,982 patent/US12157767B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201118T1 (hr) | Izolacija i pročišćavanje prot-il-13 protutijela uporabom protein a afinitetne kromatografije | |
| US10053489B2 (en) | Method for purifying antibody | |
| DK2791176T3 (en) | PROCEDURE FOR CLEANING ANTIBODIES | |
| RU2603347C2 (ru) | Очистка белка с использованием бис-трис буфера | |
| CN102762585B (zh) | 单一单元抗体纯化 | |
| TWI596107B (zh) | 單株抗體之新穎純化方法 | |
| JP7729857B2 (ja) | プロテインａクロマトグラフィー中の不純物の除去を促進する方法 | |
| RU2011120174A (ru) | Инактивация вируса при очистке антител | |
| US20190330269A1 (en) | Method for purifying antibodies using pbs | |
| US20160347833A1 (en) | Antibody process | |
| JP6068442B2 (ja) | 標的分子精製におけるｄｎａ除去法 | |
| JP7780430B2 (ja) | イオン交換クロマトグラフィー中に抗体収率を増加させるための方法 | |
| CN114729002A (zh) | 抗体色谱过程中的洗脱液收集 | |
| US20250188120A1 (en) | Affinity chromatographic production of clinical human igg products | |
| JP7621284B2 (ja) | 着色を抑制したポリペプチドを含む組成物の製造方法 | |
| JP2014529330A (ja) | 単一ユニットクロマトグラフィー抗体精製 | |
| KR102899514B1 (ko) | 분리 방법 | |
| CN120152772A (zh) | 用于清洁的组合物和方法 | |
| WO2018045587A1 (zh) | 一种抗vegf类单克隆抗体的纯化方法 | |
| EP2782925B1 (en) | Protein purification using bis-tris buffer |